The debate over pharmaceutical pricing policies and access to AIDS-related drug treatment has greatly intensified over the past year. In this context, along with a succession of price reductions, several research-based pharmaceutical manufacturers have instituted donation programs as a response to the need for improved access to these drugs by HIV-infected persons in the developing world. The purpose of this paper is to examine Merck's Mectizan (ivermectin)...
Voir la suite
INFORMATION
-
2002/01/01
-
Document de travail
-
31570
-
1
-
1
-
2005/08/02
-
Disclosed
-
The Mectizan (ivermectin) Donation Program for Riverblindness as a paradigm for pharmaceutical industry donation programs
-
Centers for Disease Control and Prevention